Arch Oncology
About:
Arch Oncology is a venture-stage biopharmaceutical company.
Website: https://www.archoncology.com/
Top Investors: SR One, Cultivation Capital, Point72, Eventide, Adage Capital Management
Description:
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
Total Funding Amount:
$250M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
St Louis, Missouri, United States
Founded Date:
2006-01-01
Contact Email:
info(AT)tiomatx.com
Founders:
Pamela Manning, William A. Frazier
Number of Employees:
11-50
Last Funding Date:
2021-04-27
IPO Status:
Private
Industries:
© 2025 bioDAO.ai